AIH and PPI tests are accepted widely to predict the therapeutic efficacy of APDs in preclinical studies (Amato et al. 2020; Gobira et al. 2013; Peleg-Raibstein et al. 2012), and, therefore, were chosen to examine the effects of DRD4 potentiation, along with the OF test. Here, DRD4 is linked to autoimmune hepatitis.